| خلاصه مقاله | Introduction
Renal transplantation is the main therapy for end stage renal diseases (ESRDs). Despite successful treatments by immunosuppressive drugs after
allogeneic transplant, there are multiple issues in finding an appropriate donor for highly sensitized patients. The aim of this study was to evaluate the
prevalence and titers of anti-HLA-class I and antiHLA-class II antibodies in highly sensitized patients. The history of the risk factors of sensitization including transplantation, blood transfusion, and pregnancy was also studied.
Patients and Methods
After selection of twenty highly sensitized ESRD candidates with a calculated panel-reactive antibody (CPRA) equal or higher than 50%, the serum titer of
Anti-HLA-I and anti-HLA-II antibodies were measured by single antigen bead (SAB) Luminex assay and reported as mean fluorescence intensity (MFI). Final
analysis were performed by SPSS software.
Results
History of renal transplantation was the most prevalent risk factor for sensitization. Blood transfusion and pregnancy were the other risk factors
Of sensitization among selected patients. Our results showed that HLA A*24:02 in anti-HLA class I and DQA1*02:01/ DQB1*06:02 in anti-HLA class II were
the most frequent antibodies. In addition, MFI levels of antibodies in anti-HLA class II was significantly higher than the MFI levels of antibodies in anti-HLA class I.
Conclusions
According to our findings, matching HLA alleles, particularly class II antibodies before transplant could reduce sensitization in the first renal transplant.
However, it is necessary to understand the sensitization status of transplant candidates by evaluating CPRA values to perform better donor matching |